Dipeptidylpeptidase 4 inhibitors—also referred to as gliptins—are oral hypoglycemic agents that have many associated potential adverse events including not only bullous pemphigoid, but also inflammatory bowel disease, multiple sclerosis, psoriasis, and thyroiditis. The gene discussed is DPP4; the disease is bullous pemphigoid.